Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central and Peripheral Insulin Resistance in T2DM
NCT06428968Recruiting
- Sponsor
- Central South University
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of Generex Oral-lyn in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Central South University. Primary endpoints: Change in Cerebral Blood Flow, Level of insulin signaling in Extracellular Vesicles of neuronal origin and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06428968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428968.